---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-007203"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:43:12.603655+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# VolitionRx Q3 revenue $475K, up 187% YoY; sold >110K Nu.Q Vet tests in 9 months

## Summary
- Q3 2024 revenue $475K, up 187% YoY; YTD revenue $1M, up 96%.
- Nu.Q Vet revenue up 307% in Q3; >110,000 tests sold in first 9 months of 2024.
- Cash used in operations $5.4M in Q3, down 36% YoY; cash balance $5.4M at Sept 30.
- Received >$2.2M in non-dilutive funding commitment from Walloon Region post-quarter.
- Reaffirms goal to be cash neutral (income matching expenditure) in 2025.

## SEC filing metadata
- accession: 0001477932-24-007203
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793224007203/0001477932-24-007203-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793224007203/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-007203
- JSON: https://secwatch.observer/filing/0001477932-24-007203.json
- Plain text: https://secwatch.observer/filing/0001477932-24-007203.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.